# REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

> clinical trial · VERIFIED · 2026-07-30

Status: ACTIVE_NOT_RECRUITING · Sponsor: Taiho Oncology, Inc. · Condition: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

- Company: Taiho Oncology, Inc.
- Sector: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
- Primary source: https://clinicaltrials.gov/study/NCT05973773

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.